Related Experiment Video
Updated: Oct 30, 2025
06:29
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
915
Weighted Gene Coexpression Network Analysis to Construct Competitive Endogenous RNA Network in Chromogenic Renal Cell
Yong-Bo Chen1, Liang Gao2, Jin-Dong Zhang3
1Department of Urology, People's Hospital of Deyang City, 173# Northern Taishan Road, Deyang 618000, China.
Biomed Research International
|July 5, 2021
Summary
This study constructed a competing endogenous RNA (ceRNA) network in chromophobe renal cell carcinoma (ChRCC), identifying key messenger RNAs (mRNAs) like CADM2 and SFRP1 as independent risk factors for patient survival.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Chromophobe renal cell carcinoma (ChRCC) is a significant subtype of kidney cancer.
- Understanding the molecular mechanisms driving ChRCC progression is crucial for developing effective treatments.
Purpose of the Study:
- To construct a competing endogenous RNA (ceRNA) network in ChRCC.
- To identify key regulatory RNAs and messenger RNAs (mRNAs) influencing patient prognosis.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) database for clinical and RNA sequencing data (mRNAs, microRNAs, lncRNAs).
- Employed differential expression analysis, weighted gene coexpression network analysis (WGCNA), and survival analysis.
- Predicted RNA interactions using multiple miRNA databases to build the ceRNA network.
Main Results:
- Identified significant numbers of differentially expressed long noncoding RNAs (DElncRNAs), microRNAs (DEmiRNAs), and messenger RNAs (DEmRNAs) in ChRCC.
- Screened 113 DElncRNAs, 14 DEmiRNAs, and 43 DEmRNAs correlated with ChRCC.
- Nine mRNAs, including CADM2 and SFRP1, significantly impacted overall survival; CADM2 and SFRP1 were identified as independent risk factors.
Conclusions:
- The constructed ceRNA network provides insights into the molecular mechanisms of ChRCC.
- Identified specific mRNAs (CADM2, SFRP1) as potential therapeutic targets for ChRCC treatment.
